Diacerein: A new symptomatic slow acting drug for osteoarthritis

JK Science

Volumn 8, Issue 3, 2006, Pages 173-175

  Mahajan, Annil ^a   Singh, Kulbir ^a   Tandon, Vishal R ^a   Kumar, Sudesh ^a   Kumar, Hardeep ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CHONDROITIN SULFATE; CYCLOOXYGENASE 2 INHIBITOR; DIACETYLRHEIN; DRUG METABOLITE; GLUCOSAMINE; INTERLEUKIN 1; PLACEBO; TENOXICAM; TETRACYCLINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; BLOOD TOXICITY; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DEFECATION HABIT; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MEAL; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; TREATMENT DURATION; URINARY EXCRETION; URINE COLOR;

EID: 33751567416     PISSN: 09721177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Arden N, Nevitt MC. Osteoarthritis epidemiology. Best Pract Clin Rheumatol 2006; 20(1): 3-25.
2. Aggarwal V. Prevalence of rheumatic diseases in India. JK Science 2003; 5(2): 48-49.
3. Mahajan A, Jasrotia DS, Manhas AS, Jamwal SS. Prevalence of major rheumatic disorders in Jammu. JK Science 2003; 5(2):63-66
4. Polisson R. Innovative therapies in osteoarthritis. Curr Rheumatol Rep 2001; 3(6): 489-95.
5. Mahajan A, Verma S, Tandon V. Osteoarthritis. JAPI 2005; 53: 634-41.
6. Colville-Nash PR, Willoughby DA. COX-1, COX-2 and articular joint disease: a role of chondroprotective agents. Biorheology 2002; 39(1-2): 171-79.
7. Mahajan A. Cox-2 inhibitors: cardiovascular safety. JK Science 2005; 7(2): 61-62.
8. Provvedini D, Cohen P. Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis. Presse Med 2002; 31 (39 Pt 2): 4S13-15.
9. Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 2006; 45(2): 129-38. Epub 2005 Nov 8.
10. Hochberg MC, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol. 2001; 15(15):583-93.
11. Moldovan F., Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerein and rhein reduce the ICE-induced IL-1 beta and IL-18 activation in human osteoarthritis cartilage. Osteoarthritis Cartilage 2000; 8: 186-96.
12. Felisaz N, Boumediene K, Ghayor C, et al. Stimulating effect of Diacerein on TGF-beta 1 and beta 2 expression in articulate chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage 1999; 7(3): 255-64.
13. Solignac M. Mechanisms of action of diacerene the first inhibitor of interleukin-1 in Osteoarthritis. Presse Med 2004; 33: S10-2.
14. Spencer CM, Wilds MI. Diacerein. Drugs 1997; 53(1): 98-106; 107-8.
15. Colville-Nash PR.comparison of pharmacological effect of diacerein and a selective COX-2 inhibitor in mouse induced glaucoma model. Presse Med 2002: 31(39 pt 2):4S16-17.
16. Nicholas P, Tod M, Padion C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet 1998; 35(5): 347-59.
17. Magnard O, Louchahi K, Tod M et al. Pharmacokinetics of diacerein in patients with liver cirrhosis. Biopharm Drug Dispos 1993; 14(5): 401-8.
18. Vignon E. Results of the ECHODIAH clinical trail on hip arthrosis. Presse Med 2002; 31 (1 Pt 2): 7-9.
19. Dougdos M, Nguyen M, Berdah L et al. Evaluation of structure modifying effect of diacerein in hip osteoarthritis :ECHODIAH, a three-year, placebo-controlled trail evalution of the chodromodulating effect of diacerein in osteoarthritis of hip. Arthritis Rheum 2001: 44(11): 2539-47.
20. Taccoen A, Berdah L. Diacetylrhein, a new therapeutic approach of osteoarthritis. Rev Rhum Ed Fr 1993; 60(6 Pt 2): 83S-6S.
21. Plletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of knee:a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000; 43(10): 2339-48.